Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Sex Cord Gonadal Stromal Tumors (SCGST) are a rare collection of ovarian and testicular neoplasms that have their distinguishing histologic features. Like any other medical condition, market dynamics surrounding SCGST diagnosis, treatment, and management is influenced by many factors. This information reveals how it affects how the SCGST market is influenced by different things. Not being as common as some cancers means that little attention or resources are given to these tumors; thus affecting research funding and pharmaceutical interest. This makes it difficult for uniform guidelines to be established in relation to treatment protocols for healthcare providers.
Another important factor within the market is advancement in technology used for diagnosing such diseases. Thus early detection and accurate diagnosis of SCGSTs can be made possible by advancing medical imaging tools, genetic testing techniques among others. Consequently, this has a bearing on the entire market through better understanding of disease and enabling of timely interventions. The availability of sophisticated diagnostic tools also determines whether new therapies will work or not as they assist in guiding targeted therapy and improving outcomes for patients with SCGSTs.
In addition to that, drug development landscape influences the market dynamics associated with SCGSTs. One major challenge is having only few drugs approved specifically for treatment of these tumors. Small populations with SCGT may prompt pharmaceutical companies from investing into dedicated drug development processes thereby reducing availability of targeted therapies. However, emerging trends on precision medicine which has shifted focus on rare diseases might possibly alter this landscape hence leading more research as well as specialized treatments in treating STSGTs.
Healthcare policies and reimbursement mechanisms represent another critical factor influencing the SCGST market. Due to high prevalence disparities exist concerning coverage/payment for diagnostic tests and treatment of these conditions among them.Thus policy makers and insurers play an integral role where they determine financial support available to patients thereby making health care accessible on managing all aspects related to STSGTs at large.
Besides patient awareness and advocacy are market factors. This means that lack of knowledge about SCGSTs among the general population, healthcare professionals up to some specialists may lead to late detection and poor treatment. Efforts made by these patient organizations and healthcare providers through their various campaigns have raised awareness about the need for more research work on this disease; thus this is a possible reason why SCSTGs gained attention from researchers and policy makers.
Therefore, involvement of different players in the healthcare industry such as researchers, clinicians, pharmaceutical companies, and patient advocacy groups is crucial for shaping the SCGST market. These include multidisciplinary approaches aimed at facilitating information exchange, collaborative research, and clinical trials which accelerate development of effective treatments. As such, it can be safely stated that market reacts positively towards those actions which promote collaboration as well as sharing knowledge since they create enabling environment which in turn speeds up the progress of researches related to STSGTs.
Sex Cord Gonadal Stromal Tumor Market Highlights:
Sex Cord-Gonadal Stromal Tumor Market Overview
Sex Cord Gonadal Stromal Tumor Market Size was valued at USD 1.42 Billion in 2023. The Global Sex Cord Gonadal Stromal Tumor industry is projected to grow from USD 1.65 Billion in 2024 to USD 3.66 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.10% during the forecast period (2024 - 2032).
The sex cord-gonadal stromal tumor is a rare type of cancer derived from the stromal component of the ovary and testis. This tumor comprises granulosa, thecal cells, and fibrocytes. Sex cord-gonadal stromal tumors are mostly of seven types, namely, granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, gynandroblastoma, Sex Cord Tumor with Annular Tubules (SCTAT), and Sertoli Leydig cell tumor. In humans, this type of tumor accounts for 8% of the ovarian cancers and around 5% of testicular cancers.
It is noted that the increasing cases of ovarian and testicular cancer, technological advancements, and increasing healthcare expenditure are the key factors driving the sex cord-gonadal stromal tumor market.
Various other factors such as the growing awareness about the cord-gonadal stromal tumor, unmet medical needs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the sex cord-gonadal stromal tumor .
Despite these drivers, there are some setbacks associated with the sex cord-gonadal stromal tumor market. Strict FDA regulations, a huge capital investment with low-profit margins, and poor healthcare system in low and middle-income countries may hinder the growth of the sex cord-gonadal stromal tumor to a considerable extent.
Sex Cord-Gonadal Stromal Tumor Market Segmentation
The global nosis, treatment, and end-user.
On the basis of tumor type, the sex cord-gonadal stromal tumor market is classified as granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, Sertoli Leydig cell tumor, gynandroblastoma, and Sex Cord Tumor with Annular Tubules (SCTAT). The granulosa cell tumor is further classified as functioning tumors and non-functioning tumors.
On the basis of diagnosis, the sex cord-gonadal stromal tumor market is classified as microscopy immunohistochemistry, tumor marker, ultrasound, Magnetic Resonance Imaging (MRI), and others. The tumor marker segment is further classified as inhibin-alpha, calretinin, Melan-A, and others.
On the basis of treatment, the sex cord-gonadal stromal tumor market is classified as chemotherapy, radiotherapy, surgery, and others. The surgery segment is further classified as salpingo-oophorectomy, abdominal hysterectomy, Retroperitoneal Lymph Node Dissection (RPLND), and radical inguinal orchiectomy. The sub-segment of salpingo-oophorectomy includes unilateral salpingo-oophorectomy and bilateral salpingo-oophorectomy.
On the basis of end-user, the sex cord-gonadal stromal tumor market is segmented into hospitals and clinics, cancer research centers, research and academic institutes, and others.
Sex Cord-Gonadal Stromal Tumor Market Regional Analysis
The Americas dominates the sex cord-gonadal stromal tumor market owing to the increasing prevalence of ovarian cancer in this region and high healthcare expenditure. According to the American Cancer Society, around 22,240 women are likely to be diagnosed with ovarian cancer, and 14,070 women are likely to die from ovarian cancer, in 2018.
Europe holds the second position in the Sexual Wellness market. The financial support provided by the government towards R&D and technological advancements are expected to drive the European sex cord-gonadal stromal tumor market. The increasing healthcare expenditure is also boosting the European sex cord-gonadal stromal tumor market.
According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014, i.e., EUR 321 billion which is further followed by France with EUR 237 billion and United Kingdom with EUR 223 billion. In the year 2016, the R&D expenditure in the pharmaceutical industry was EUR 35000 million, suggested by the European Federation of Pharmaceutical Industries and Association.
Asia Pacific is the fastest growing sex cord-gonadal stromal tumor market owing to a huge patient pool and development in the pharmaceutical sector. Healthcare expenditure is found to be boosting in various regions of Asia Pacific. As per the data suggested by the Australian Institute of Health and Welfare during the year 2015–2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014–2015.
The Middle East and Africa holds the lowest share of the global market due to slow development, lack of technical knowledge, and poor medical facilities.
Sex Cord Gonadal Stromal Tumor Market Key Players
- Abbott
- Abcam plc
- Affymetrix, Inc.
- Agilent Technologies, Inc.
- Beckman
- Dickinson and Company (BD)
- Bio SB Inc.
- BioCurex
- BioModa Inc.
- Bio-Rad Laboratories Inc.
- Boston Scientific Corporation
- Cell Signaling Technology, Inc.
- Clarient Inc.
- CooperSurgical Inc.
- Correlogic Systems Inc.
- Danaher Corporation
- Epigenomics AG
- F. Hoffmann-La Roche AG
- Gen-Probe Inc.
- Hologic Inc.
- Johnson & Johnson Services Inc.
- Karl Storz GmbH & Co. Kg
- LiNA Medical USA
- Merck Millipore
- PerkinElmer Inc.
- Qiagen
- Radient Pharmaceuticals
- Thermo Fisher Scientific Inc.
- Veridex LLC
Recent Development
November 2023: OncoCell MDx announces the launch of its new OncoCell GIST test, a molecular diagnostic test for the detection of genetic mutations associated with sex cord-gonadal stromal tumors (SCGSTs). The OncoCell GIST test is designed to help clinicians diagnose SCGSTs more accurately and efficiently, and to guide treatment decisions.
October 2023: Bio-Rad Laboratories, Inc. announces the launch of its new QX200 Droplet Digital PCR (ddPCR) System, a ddPCR system that is designed to provide researchers with a more accurate and sensitive way to detect and quantify genetic mutations associated with SCGSTs.
September 2023: Thermo Fisher Scientific, Inc. announces the launch of its new Oncomine Focus Dx NGS Panel, a next-generation sequencing (NGS) panel that is designed to detect and quantify genetic mutations associated with SCGSTs and other rare cancers.
August 2023: QIAGEN N.V. announces the launch of its new Rotor-Gene Q MDx PCR System, a qPCR system that is designed to provide clinicians with a rapid and accurate way to detect genetic mutations associated with SCGSTs.
July 2023: Roche Diagnostics announces the launch of its new cobas 4800 System, a real-time PCR system that is designed to provide clinicians with a high-throughput and accurate way to detect genetic mutations associated with SCGSTs.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
